Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells-Reference-Cited by-同舟云学术

Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells

Published:2021-07-28 Issue:17 Volume:25 Page:8187-8200
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Nalairndran Geetha¹,Chung Ivy¹²^ORCID,Abdul Razack Azad Hassan³,Chung Felicia Fei‐Lei⁴,Hii Ling‐Wei⁵⁶⁷,Lim Wei‐Meng⁵⁶,Looi Chin King⁵⁷,Mai Chun‐Wai⁵⁸,Leong Chee‐Onn⁵⁶^ORCID

Affiliation:

1. Department of Pharmacology Faculty of Medicine University of Malaya Kuala Lumpur Malaysia

2. University of Malaya Cancer Research Institute Faculty of Medicine University of Malaya Kuala Lumpur Malaysia

3. Department of Surgery Faculty of Medicine University of Malaya Kuala Lumpur Malaysia

4. Mechanisms of Carcinogenesis Section (MCA) Epigenetics Group (EGE) International Agency for Research on Cancer World Health Organization Lyon CEDEX 08 France

5. Center for Cancer and Stem Cell Research Institute for Research Development and Innovation (IRDI) International Medical University Kuala Lumpur Malaysia

6. School of Pharmacy International Medical University Kuala Lumpur Malaysia

7. School of Postgraduate Studies International Medical University Kuala Lumpur Malaysia

8. State Key Laboratory of Oncogenes and Related Genes Renji‐Med X Clinical Stem Cell Research Center Department of Urology Ren Ji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China

Funder

Ministry of Higher Education, Malaysia

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.16684

Reference88 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study

3. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)